Premium
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Author(s) -
Birdwell KA,
Decker B,
Barbarino JM,
Peterson JF,
Stein CM,
Sadee W,
Wang D,
Vinks AA,
He Y,
Swen JJ,
Leeder JS,
Schaik RHN,
Thummel KE,
Klein TE,
Caudle KE,
MacPhee IAM
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.113
Subject(s) - tacrolimus , dosing , cyp3a5 , pharmacogenetics , medicine , therapeutic drug monitoring , genotype , pharmacology , transplantation , pharmacokinetics , biology , gene , biochemistry
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org ).